Tuesday, 16 Jul 2019

You are here

RheumNow Podcast – Loretta Lynn Arthritis (3.29.19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

  1. 340 CCP+ persons without followed for 1047 PYrs = 21.5% developed RA. Risk of RA progression increased w/ CCP level. 46.0% of high level CCP patients progressedto RA by 5 years. High vs low CCP were 5 times more likely to get RA (HR 4.83, 95%CI 2.51-9.31). https://buff.ly/2FI5Dix 
  2. Claims data analysis of 11,248 matched patients starting abatacept or TNFi showed the risk of hospitalized infection was 37 ABA vs 47 TNFi (HR 0.78; 95% CI 0.64-0.95). Thus ABA was associated with a 22% less risk any hospitalized infection. https://t.co/Ij6b0IYcAZ 
  3. 2019 Doximity report shows Rheumatologists are the 14th lowest paid of all medical specialties; but is amongst the lowest with a gender gap difference. check it out here https://t.co/j3YOybQ78n 
  4. Murine BM–derived macrophages or human monocytes treated w/ tofacitinib or selective JAK1, JAK3 inhibitors. Both TOFA & JAK1i but not JAK3i effectively inhibited STAT1 phosphorylation & IFN gamma production, suggesting affects on macrophage function. https://t.co/qILxzCDrCH   
  5. Boehringer Ingelheim announce s FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD https://t.co/BQz94Kg4Px     
  6. After either RTX or CTX induction, 102 pts w/ ANCA-associated vasculitis were give maintenance w/ azathioprine plus belimumab or placebo. Belimumab did not reduce the flare rate (HR=1.07;) or relapse (HR=0.88) (NS) in these patients https://t.co/5EgdzRRXq8   
  7. Coal miners at higher risk for any arthritis (HR 2.3) and rheumatoid arthritis (HR 3.6) https://t.co/OKx9LiADWw 
  8. Serum soluble programmed cell death protein 1 (sPD-1) shown to correlate w/ BVAS activity in 59 pts w/ ANCA-associated vasculitis (AAV). sPD-1 was correlated with hemoglobin and serum albumin, but not ESR or CRP. https://t.co/GOShh8Kwb2 
  9. Prevalence of gout continues to rise. NHANES data say prevalence of gout is 9.2 million inUS adults (2015-2016) (5.9 mill men; 3.3 mil women); hyperuricemia prevalences is 20.0%. ULT use in gout was 33% between 2007-2014. https://t.co/nDEJM7gTGA   
  10. FDA Approves Cimzia for Non-Radiographic Axial Spondyloarthritis  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – Boiling Hot MAS (7.12.19)

Dr. Jack Cush reviews this week's news and journal reports featured on RheumNow.com. PsA v. non-PsA pregnancies, Still's disease, lupus, nutritional supplements and dietary interventions, use of cannabis, tanezumab in OA, CBD oils and more.

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and more.

EULAR 2019 – Day 3 Report

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.

Ultrasound Reveals Which Anti-CCP Positive Patients Progress to Arthritis 

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Power Doppler signal on baseline ultrasound exam may well help stratify anti-CCP positive patients with musculoskeletal symptoms but no clinical synovitis, according to data from the Leeds Institute of Rheumatic and Musculoskeletal Medicine presented at EULAR 2019.